Invention Grant
- Patent Title: Targeting the EGFR-SGLT1 interaction for cancer therapy
-
Application No.: US15139066Application Date: 2016-04-26
-
Publication No.: US09770482B2Publication Date: 2017-09-26
- Inventor: Zhang Weihua
- Applicant: The University of Houston System
- Applicant Address: US TX Houston
- Assignee: The University of Houston System
- Current Assignee: The University of Houston System
- Current Assignee Address: US TX Houston
- Agency: Blank Rome LLP
- Main IPC: A61K38/10
- IPC: A61K38/10 ; A61K31/517 ; A61K31/519 ; A61K31/5377 ; C07K7/08 ; A61K45/06 ; A61K31/7042 ; A61K31/70 ; A61K31/422 ; A61K31/7034 ; A61K38/17
Abstract:
A compound can destabilize an epidermal growth factor receptor (EGFR) protein and a sodium/glucose co-transporter 1 (SGLT 1) protein. In one embodiment, the compound is a peptide derived from the interacting domain of EGFR. In another embodiment, the peptide is administered to a patient to treat cancer.
Public/Granted literature
- US20160228495A1 Targeting the EGFR-SGLT1 Interaction for Cancer Therapy Public/Granted day:2016-08-11
Information query
IPC分类:
